 NEW YORK, Nov. 09, 2020 GLOBE NEWSWIRE -- Axovant Gene Therapies Ltd. NASDAQ: AXGT, a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration FDA has lifted its clinical hold and cleared the Investigational New Drug IND Application to initiate a registrational study of AXO-AAV-GM2 gene therapy to treat patients with Tay-Sachs disease and Sandhoff disease. AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA indicating that it has satisfactorily addressed all issues related to the clinical hold. 